Our History of Advancing Science
Established in 2003 by world-renowned researchers, our history is deeply rooted in science and our research and development efforts are focused on disease areas with significant unmet need for new treatment options to help improve the lives of patients.
Radius initiated the Phase 3 wearABLe study to evaluate the efficacy and safety of abaloparatide-patch for the treatment of postmenopausal women with osteoporosis.
Radius initiated its Phase 3 EMERALD study, a randomized, open label, active-controlled study evaluating elacestrant as second- or third-line monotherapy in advanced/metastatic ER-positive (ER+)/HER2-negative (HER2-) breast cancer patients.
Radius initiated the Phase 3 ATOM (Abaloparatide Treatment for Osteoporosis in Males) study of abaloparatide injection for the treatment of osteoporosis in men.
Radius announced scale-up and commercial supply agreement with 3M to exclusively manufacture commercial supplies of abaloparatide patch.
Radius provided update on data from the clinical studies of elacestrant during the 2017 San Antonio Breast Cancer Symposium (SABCS).
U.S. Food and Drug Administration granted Fast Track designation for elacestrant.
Radius initiated Phase 1 study of RAD140, an internally developed selective androgen receptor modulator (SARM) undergoing clinical evaluation for the treatment of hormone receptor positive breast cancer.
Jesper Høiland appointed President and Chief Executive Officer.
Radius presented update on data from ongoing study of elacestrant at the American Society of Clinical Oncology (ASCO) Meeting.
TYMLOS® (abaloparatide) injection was approved on April 28, 2017 by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Radius presented data from two ongoing Phase 1 studies of elacestrant in patients with estrogen receptor positive (ER+) breast cancer at the San Antonio Breast Cancer Symposium (SABCS).
Radius’ NDA for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis accepted for filing by the U.S. Food and Drug Administration.
Radius commenced a Phase 1 FES-PET study in patients with metastatic breast cancer in the European Union, which includes the use of FES-PET imaging to assess estrogen receptor occupancy in tumor lesions following elacestrant treatment.
Radius presented data from the first six months of ACTIVExtend trial during the American Society for Bone and Mineral Research (ASBMR) Annual Meeting.
Radius presented data from the Phase 3 ACTIVE (Abaloparatide Comparator Trial In Vertebral Endpoints) trial during the Endocrine Society (ENDO) Annual Meeting.
Radius commenced elacestrant Phase 1 study in postmenopausal women with ER+ and HER2- advanced breast cancer in the United States.
Radius completed successful IPO.
Abaloparatide-SC Phase 3 extension study (ACTIVExtend) commenced.
Radius and 3M Drug Delivery Systems announced exclusive agreement for development of abaloparatide patch.
Radius initiated Phase 2 Study of Abaloparatide-patch for the Treatment of Postmenopausal Osteoporosis.
Abaloparatide-SC Phase 3 ACTIVE (Abaloparatide Comparator Trial In Vertebral Endpoints) trial initiated in postmenopausal women with osteoporosis.
Abaloparatide-SC Phase 2 trial initiated in postmenopausal women with osteoporosis.
Radius in-licensed elacestrant (RAD1901), a selective estrogen receptor degrader (SERD).
Nuvios became Radius Health, Inc.
Nuvios in-licensed abaloparatide.
- Possible bone cancer (osteosarcoma). During animal drug testing, TYMLOS caused some rats to develop a bone cancer called osteosarcoma. It is not known if people who take TYMLOS will have a higher chance of getting osteosarcoma.
- Tell your healthcare provider right away if you have pain in your bones, pain in any areas of your body that does not go away, or any new or unusual lumps or swelling under your skin that is tender to touch.
- have Paget’s disease of the bone or other bone disease, will have trouble injecting yourself with the TYMLOS pen and do not have someone who can help you
- have or have had cancer in your bones, have or have had radiation therapy involving your bones, have or have had too much calcium in your blood, have or have had too much of an enzyme called alkaline phosphatase in your blood, have or have had an increase in your parathyroid hormone (hyperparathyroidism)
- are pregnant or plan to become pregnant because TYMLOS is not for pregnant women, or are breastfeeding or plan to breastfeed. It is not known if TYMLOS passes into your breast milk. You and your healthcare provider should decide if you will take TYMLOS or breastfeed. You should not do both.
- Decrease in blood pressure when you change positions. Some people may feel dizzy, have a faster heartbeat, or feel lightheaded soon after the TYMLOS injection is given. These symptoms generally go away within a few hours. Take your injections of TYMLOS in a place where you can sit or lie down right away if you get these symptoms. If your symptoms get worse or do not go away, stop taking TYMLOS and call your healthcare provider.
- Increased blood calcium (hypercalcemia). TYMLOS can cause some people to have a higher blood calcium level than normal. Your healthcare provider may check your blood calcium before you start and during your treatment with TYMLOS. Tell your healthcare provider if you have nausea, vomiting, constipation, low energy, or muscle weakness. These may be signs there is too much calcium in your blood.
- Increased urine calcium (hypercalciuria). TYMLOS can cause some people to have higher levels of calcium in their urine than normal. Increased calcium may also cause you to develop kidney stones (urolithiasis) in your kidneys, bladder or urinary tract. Tell your healthcare provider right away if you get any symptoms of kidney stones which may include pain in your lower back or lower stomach area, pain when you urinate, or blood in your urine.
- If you take more TYMLOS than prescribed you may experience symptoms such as muscle weakness, low energy, headache, nausea, dizziness (especially when getting up after sitting for a while) and a faster heartbeat. Stop taking TYMLOS and call your healthcare provider right away.
- decrease the chance of having a fracture of the spine and other bones in postmenopausal women with thinning and weakening bones (osteoporosis).
- treat osteoporosis in postmenopausal women who are at high risk for bone fracture.
IMPORTANT SAFETY INFORMATION FOR TYMLOS
What is the most important information I should know about TYMLOS?
TYMLOS may cause serious side effects including:
Before you take TYMLOS, tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
What are the possible side effects of TYMLOS?
TYMLOS can cause serious side effects including:
The most common side effects of TYMLOS include: dizziness, nausea, headache, fast heartbeat, feeling very tired (fatigue), upper stomach pain, vertigo
These are not all the possible side effects of TYMLOS. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is TYMLOS?
TYMLOS is a prescription medicine used to:
It is not known if TYMLOS is safe and effective for children 18 years and younger.
It is not recommended that people use TYMLOS for more than 2 years during their lifetime.
TYMLOS should not be used in children and young adults whose bones are still growing.